Aegerion Pharmaceuticals, Inc. (AEGR) Message Board

Did Bayer run a trial with patients taking 1 aspirin per day?
and
A trial with patients taking 2 aspirins per day?
and
A trial with patients taking 3 aspirins per day?
and
A trial with patients taking 2 aspirins at one time?
and
A trial with patients taking 4 aspirins at one time?
and
A 100 more trials with other possible variations to determine the proper dosage and plasma levels?

DID THE FDA REQUEST THAT OF BAYER?

They could buy some shares in the open market now and push the pps higher and then make a tender offer for the remaining shares. That would save them $millions.
Let's say that they could accumulate 25M shares at an average price of .80.
Their total acquisition price would drop by abut $50M.
That's a strategy that they could pursue.

Once they acquired about 5M shares, they would have to disclose it, and the pps would spike.
So it's doubtful if they would be able to buy 25M shares at an average price of .80.

MAPP shareholders didn't sell after the CRL.
TTNP shareholders were chicken sheets.

How do you tell one from the other?

That's precious! INO has a partnership agreement to potentially receive royalties from its own subsidiary.

Observe the following three rules you'll never again have to watch you stock drop from $50.00 to $00.50:
1) NEVER buy a stock that has had more name changes than Elizabeth Taylor had husbands.
2) NEVER buy a stock that has had a reverse stock split.
3) NEVER buy a stock that had 44 million shares in March 2009 and 233 million shares in March 2013

How much is a FAILED Hep C program worth?

"The cards are down for Inovio (INO) investors after the company announced negative data from its collaborative clinical trial with ChronTech AB of Sweden on a Hepatitis C vaccine. Namely, the company reported that the initial results did not show a statistically significant difference between treatment outcomes of the vaccinated and non-vaccinated groups."

YOU SHOULD KNOW BY NOW, INO HAS NEVER ADVANCED A DRUG PAST P2.........30 YEARS AND COUNTING!

"Inovio Pharmaceuticals, however, caught my eye a while back when it started making overly positive statements about a platform (DNA vaccines) that has failed repeatedly in Phase II human trials. As a reviewer for dozens of scientific journals, it is my opinion that Inovio's scientific team is not up to the task of designing an appropriate clinical trial to meet its stated outcomes. Furthermore, I fail to understand why the company repeatedly uses such low sample sizes that are statistically questionable, especially when the diseases in question are not rare. In conclusion, I think this recent press release should raise significant questions for investors holding out hope that Inovio will right the ship. I humbly suggest that investors steer clear of this company, as its press releases beg more questions than they answer."

I'd put my money on Hugo, INO looks like dung, if not an outright scam.

Let's play rearranging deck chairs. Is that a fun game?

Inovio which was formerly Concord Energy, United Safety Technology, BTX Inc., Genetronics and numerous other names is really VGX Pharmaceuticals? Is that your brilliant spin? Let's sweep Inovio's sordid history under the rug and let's go with the thesis that Inovio is really VGX.

What do we know about VGX? It was founded in 2001 as Viral Genomix and then changed its name to VGX Phrmaceuticals. In 2005, Inovio acquired an equity interest in VGX. In 2007, VGX's lead drug, PICTOVIR a/k/a VGX-410c failed in P2 and further trials were discontinued. In 2009 Inovio held a 19.65% equity interest in VGX and the two companies agreed to merge.

VGX is what you are crowing about? You might have a better case arguing that Inovio is really Concord Energy.

Inovio now owns a 30% interest in VGX International, a company that was founded in Korea in 1976. Its lead drug for the swine flu is in P1. It has taken VGX 37 years to get a drug into P1. VGX and Inovio are a match made in heaven. When the swine flue makes a reappearance 40 years from now, it will be huge for INO!

In Oct. 2011, the following announcement was made:
" -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of synthetic vaccines against cancers and infectious diseases, announced today that it has entered into a product development collaboration agreement with its affiliate, VGX International Inc. (KSE:011000), to co-develop Inovio's SynCon® therapeutic vaccines for hepatitis B and C infections.

Under the terms of the agreement, VGX International will receive marketing rights for these vaccines in Asia, excluding Japan, and in return will fully fund IND-enabling and initial phase I and II clinical studies. Inovio will receive payments based on the achievement of clinical milestones and royalties based on sales in the licensed territories and retains all commercial rights in all other territories."

That's precious! INO has a partnership agreement to potentially receive royalties from its own subsidiary.

Observe the following three rules and you'll never again have to watch you stock drop from $50.00 to $00.50:
1) NEVER buy a stock that has had more name changes than Elizabeth Taylor had husbands.
2) NEVER buy a stock that has had a reverse stock split.
3) NEVER buy a stock that had 44 million shares in March 2009 and 233 million shares in March 2013.

More from Hugo:

"In 1979, INO was a Canadian company, Concord Energy. Then it became United Safety Technology. After that it was Consolidated United States Technology. In 1983, when biotechs were hot, it morphed into Genetronics Biomedical and hyped its electroporation technology.

In 1999, the Company conducted two P2 trials using its electroporation system and 22 million shares were outstanding. Fast forward 24 years to 2013, the Company is now known as Inovio, and it is still only in P2 peddling its failed electroporation technology, but now the share count is the equivalent of over 900 million shares.

We are speaking about a Company that has camouflaged its past and a Company that has inflicted hundreds of millions of dollars of losses on trusting investors.

In 5 years, will the Company be reincarnated as a green energy company or will it still be in P2 peddling its 30 year old failed electroporation technology to a new crop of unsuspecting investors?"

What you don't understand is that ACAD's drug, which probably won't get approved, is for Parkinson's patients with psychosis. TTNP had Fanapt approved for the $40 billion psychosis market. TTNP didn't reach a market cap of $1 billion. There are some 8 approved drugs for psychosis and several generics. ACAD wants to market its drug to a small subset of the psychosis market, just Parkinson's patients with psychosis. ACAD is late to class and last in class.

So the market for Pimavanserin is $400 million and they are no way close to approval.
The market for Probuphine is estimated to be $400 million out of the total market of $1.5 billion.

There is potential for $1 billion in sales for Alzheimers?
There is the potential for $1 billion in sales of Probuphine for chronic pain.

ACAD is no where near approval and TTNP is on the door step of approval.
TTNP will be marketing a drug that has already been approved (buprenorphine).
ACAD's drug might be unapprovable.

Either ACAD is grossly overpriced or TTNP is grossly undervalued, or both.

There are lots of "ifs" with ACAD, your dissertation listed a half dozen of them.
I wouldn't pay a billion dollars for "ifs", even with your imaginary money.

Hey, PATH has an approved drug for migraines.
Do you know what the market size is for migraine treatments and what PATH's market cap is?

You can shove you foolish ACAD pumps up your pipe an smoke it.
ACAD will be back to $1 on the CRL, if they ever file a NDA.

Anybody who toots his own horn while at the same time slapping himself on the back is a blowhard and a loser who deludes himself and tries to impress other without success.

It's time to read some reasoned facts.